ANRO Alto Neuroscience, Inc.

NYSE
$26.49

Alto Neuroscience, Inc. (ANRO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.7% since its last earnings release on August 12, 2026.

Alto Neuroscience Beat Consensus Estimates
Wednesday, August 12, 2026 · 4:03 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.60)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $32.96

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alto Neuroscience, Inc.

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.